Long-term results from the phase III TRIANGLE trial show ibrutinib-based regimens improve survival in younger mantle cell lymphoma patients, while the ECHO trial establishes a new standard for older patients. Advances in CAR T-cell and bispecific antibody therapies are reshaping treatment for this rare blood cancer. The findings were presented at the annual MCL Consortium meeting.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774234 |
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07748364 |
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics |
NOT_YET_RECRUITING | PHASE2 |
| NCT07724457 |
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07717177 |
AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL |
NOT_YET_RECRUITING | PHASE2 |
| NCT07711483 |
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07695896 |
Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
NOT_YET_RECRUITING | |
| NCT07649304 |
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") |
NOT_YET_RECRUITING | PHASE1 |
| NCT07634289 |
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07599423 |
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07528352 |
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL |
RECRUITING | PHASE1 |
